Dupixent is now approved in India for the treatment of adults with moderate-to-severe atopic dermatitis

Briefs: Link Pharma Chem and Zydus

USFDA concludes inspection at Zydus' formulation manufacturing facility at SEZ 2, Ahmedabad

L V Prasad Eye Institute and Indian Oil sign MoU to provide care to children with eye cancer

The collaboration aims to raise awareness about eye cancer, provide medical and surgical treatment support to children and supply nutritional supplements to aid in their faster recovery.

Lupin achieves milestone for its phase 1 clinical stage MALT1 inhibitor program

Lupin has received US$ 25 million from AbbVie for initiation of Phase 1 clinical studies successfully

Natural Capsules announces strategic investment by Somerset Indus Capital Partners

Lupin signs MoU with Govt. of Maharashtra to combat rising prevalence of cardiovascular diseases

The partnership aims to prioritize the diagnosis and treatment of these diseases while working to reducing their long-term prevalence

Lupin receives EIR from FDA for its API manufacturing facility in Vizag

The inspection closed with the facility receiving an inspection classification of NAI

Granules India receives ANDA approval for Levetiracetam Tablets

Granules now has a total of 58 ANDA approvals from US FDA

Zydus receives final approval from the USFDA for Diclofenac Sodium and Misoprostol Delayed Release Tablets

Diclofenac Sodium and Misoprostol Delayed Release Tablets USP, 50mg/200 mcg and 75mg/200 mcg had annual sales of USD 13 mn in the United States

Briefs: Ipca Laboratories, Lupin and Zydus

The company has extended its full co-operation and support to the officials of the Income Tax Department